<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Non-African Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> is a <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare disease</z:e> among adults without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Among 1352 Greek adult patients with non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, 24 cases (1.8%) were classified as Burkitt's (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) or Burkitt-like (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e>) <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Eleven cases fulfilled the criteria of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and 13 of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>No statistical differences were found in the general characteristics of the two groups at the time of diagnosis </plain></SENT>
<SENT sid="4" pm="."><plain>Extranodal involvement was a common finding in both groups and bulky disease (&gt;10 cm) was observed in almost one half of the patients </plain></SENT>
<SENT sid="5" pm="."><plain>The majority of the patients were treated with intensive, although different, protocols </plain></SENT>
<SENT sid="6" pm="."><plain>After induction treatment, complete remission (CR) was achieved in 14 patients (60.8%) </plain></SENT>
<SENT sid="7" pm="."><plain>CR was reached in <z:hpo ids='HP_0000001'>all</z:hpo> cases with stage I-II, while in stage IV the CR rate was 30.4% </plain></SENT>
<SENT sid="8" pm="."><plain>The median overall survival was 27 months </plain></SENT>
<SENT sid="9" pm="."><plain>The median survival for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> was 13 months compared to 27 months in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> group (P=0.34) </plain></SENT>
<SENT sid="10" pm="."><plain>The data of the present retrospective analysis, indicated that there were not significant clinical differences between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> variants </plain></SENT>
<SENT sid="11" pm="."><plain>Since <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BLL</z:e> is still a non-reproducible category in the REAL classification, <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> variants must be treated uniformly with intensive protocols </plain></SENT>
</text></document>